Skip to main content

Table 6 Multivariate analysis in NSCLC

From: The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study

 

PFS

OS

Univariate

Multivariate

Univariate

Multivariate

HR

95% CI

p value

HR

95% CI

p value

HR

95% CI

p value

HR

95% CI

p value

ECOG

 0 or 1

1.0

 

0.005

1.0

 

0.003

1.0

 

0.006

1.0

 

0.015

 2 or 3

2.316

1.281–4.187

 

3.945

1.573–9.896

 

2.464

1.288–4.711

 

3.894

1.301–11.660

 

ICI

 Nivolumab

1.0

 

0.891

   

1.0

 

0.363

1.0

 

0.039

 Pembrolizumab

1.115

0.716–1.736

0.631

   

1.31

0.790–2.173

0.295

3.342

1.187–9.411

0.022

 Others

1.043

0.595–1.828

0.884

   

0.801

0.410–1.564

0.516

2.651

0.676–10.403

0.162

Stage

 III

1.0

 

0.101

1.0

 

0.141

1.0

 

0.216

1.0

 

0.127

 IV

3.241

0.794–13.223

 

4.645

0.601–35.859

 

2.439

0.593–10.030

 

5.747

0.610–54.146

 

Number of metastatic organ

 0 or 1

1.0

 

0.007

1.0

 

0.078

1.0

 

< 0.001

1.0

 

0.014

 ≥ 2

1.754

1.170–2.630

 

1.681

0.943–2.996

 

2.732

1.697–4.397

 

2.401

1.193–4.830

 

Brain metastasis

 No

1.0

 

0.502

1.0

 

0.026

1.0

 

0.979

1.0

 

0.112

 Yes

0.832

0.485–1.425

 

0.373

0.157–0.890

 

1.008

0.553–1.836

 

0.398

0.128–1.241

 

Number of treatment line

 1st

1.0

 

0.064

   

1.0

 

0.324

   

 2nd

1.484

0.911–2.418

0.113

   

1.245

0.717–2.163

0.437

   

 ≥ 3rd

1.855

1.102–3.121

0.02

   

1.568

0.871–2.822

0.134

   

Clinical trial

 Yes

1.0

 

0.032

1.0

 

0.011

1.0

 

0.018

1.0

 

0.031

 No

1.554

1.039–2.324

 

2.35

1.217–4.537

 

1.782

1.104–2.877

 

3.27

1.116–9.584

 

Histologic subtype

 Adenocarcinoma

1.0

 

0.768

   

1.0

 

0.855

   

 Squamous cell carcinoma

1.064

0.703–1.610

    

0.956

0.59.-1.542

    

PD-L1

 Negative

  

0.226

1.0

 

0.064

1.0

 

0.396

1.0

 

0.024

 Low

1.723

0.776–3.827

0.181

0.952

0.372–2.440

0.919

1.839

0.676–4.999

0.233

0.802

0.229–2.817

0.731

 High

1.165

0.546–2.486

0.693

0.447

0.179–1.117

0.085

1.329

0.515–3.433

0.557

0.218

0.055–0.866

0.030

EGFR

 Negative

1.0

 

0.196

1.0

 

0.061

1.0

 

0.376

1.0

 

0.072

 Positive

1.554

0.796–3.031

 

2.574

0.956–6.929

 

1.401

0.664–2.956

 

2.964

0.906–9.695

 

Antibiotics before ICI

 No

1.0

 

0.001

1.0

 

0.006

1.0

 

< 0.001

1.0

 

0.001

 Yes

1.948

1.310–2.898

 

2.379

1.281–4.418

 

2.476

1.568–3.911

 

3.834

1.736–8.469

 
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us